Dronedarone

概要

論文の詳細を見る
Dronedarone, the derivative of amiodarone have been proved as a first line therapy for atrial fibrillation (AF). Similar to those in amiodarone, dronedarone have multiple channel effects, which include class I, II, III and IV. However, dronedarone has been considered to be a more atrial-specific anti-arrhythmic agent and can reduce ultrarapid delayed rectifier (IKur) and acetylcholine-dependent (IKAch) potassium currents. Moreover, dronedarone contains stronger inhibitory effects on sodium currents. Therefore, dronedarone was effectively in reducing AF occurrences and decrease the ventricular responses during AF attack. Chronic administration of dronedarone prolongs the action potential duration and reduces the maximum upstroke sloe of the action potential (Vmax) in atrial myocytes. In addition, dronedarone reduces the spontaneous activity in sinus node and pulmonary vein cardiomyocytes. Dronedarone can prolong the QT interval with a dose-dependent manner but has little effects on the occurrences of early afterdepolarization, which can be cause by its multiple channels effects or inconsistent effects on different ventricular myocytes. Dronedarone has been found to significantly prolong the time to AF recurrence, decrease ventricular rates, and reduce unplanned cardiovascular hospitalisation and stroke. These beneficial effects may be caused by it's rate control and rhythm control ability. In conclusion, dronedarone has both rhythm control and rate control potential for treating AF.
日本不整脈学会の論文

Dronedarone

スポンサーリンク

概要

著者

関連論文

スポンサーリンク